The authors claimed that detection of AnxA6 might not only be useful as a potential biomarker for specific breast cancer subtypes but might also be a promising predictor of especially basal-like TNBC to targeted therapeutic interventions. This evidence concerns the gene ANXA6 and breast carcinoma.